ArticleJAMA health forum2025
Estimates of Illicit Opioid Use in the US.
Article in JAMA health forum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Genetic variation in BDNF is associated with opioid use disorder severity.Human genetics · 2026Article
- Longitudinal patterns of fentanyl utilisation (medical versus illicit sources) in the United States 2015-2023: a retrospective cohort study.EClinicalMedicine · 2026Article
- Retention in Telehealth-Delivered Buprenorphine Treatment for Opioid Use Disorder: Multistate Retrospective Cohort Study.Journal of medical Internet research · 2026Article
- Transitions from first drug use to illicit opioid and injection drug use in a multisite rural U.S. cohort of people who use drugs.Harm reduction journal · 2026Article
- Long-Acting Naltrexone Restores Network Connectivity in Subjects With Comorbid Cannabis and Opioid Use Disorder.Addiction biology · 2026Article
- Potentiation of fentanyl-induced respiratory depression by alcohol is not fully reversed by naloxone.JCI insight · 2026Article
- Regulating quasi-legal markets: Evidence from pain management clinic laws.Journal of public economics · 2025Article
- Proactive Bias Mitigation When Using Online Survey Panels for Self-Reported Use of Illicitly Manufactured Fentanyl in the General Adult Population.JAMA health forum · 2025Article
- Long-acting naltrexone restores network connectivity in subjects with co-morbid cannabis and opioid use disorder.bioRxiv : the preprint server for biology · 2025Article
- Postoperative Opioid Prescribing Among Adults with Disabilities After a Medicare Opioid Limit Policy.Annals of surgery · 2025Article
- Error in Results Section.JAMA health forum · 2025Article
- Early estimates of awareness and uptake of over-the-counter naloxone.Health affairs scholar · 2025Article
- Primary Care Clinicians' Attitudes on Digital Care Collaborative Management for Substance Use Disorders.Inquiry : a journal of medical care organization, provision and financingArticle
Corrections and comments
- Erratum issued
Authors and funding
2 authors.
Funding
Abstract
Importance: Illicit opioids, particularly illicitly manufactured fentanyl (IMF), are major contributors to overdose deaths in the US. Understanding the prevalence and characteristics of illicit opioid use is crucial for addressing the opioid crisis. Objective: To estimate the prevalence of illicit opioid use, including IMF, and initial opioid exposure among those reporting illicit opioid use. Design, Setting, and Participants: This cross-sectional study was conducted using an online survey with targeted demographic quotas from June 10, 2024, to June 17, 2024. A total of 1515 participants aged 18 years and older from the US completed the survey. The analysis was conducted between June 30, 2024, and February 13, 2025. Main Outcomes and Measures: The primary outcome was self-reported illicit opioid use within the past 12 months. Secondary outcomes included initial exposure to opioids and perceived likelihood of overdose. Logistic regression was used to analyze associations with demographic and geographic factors. Results: A total of 1515 respondents completed the survey, including 770 female individuals (50.8%), 20 American Indian or Alaska Native (1.3%), 101 Asian or Pacific Islander (6.7%), 215 Black (14.2%), 1087 White (81.7%), and 24 multiracial (1.6%); 186 (12.3%) were aged 18 to 24, 242 (16.0%) 25 to 34, 327 (21.6%) 35 to 44, 280 (18.5%) 45 to 54, 281 (18.5%) 55 to 64, 139 (9.2%) 65 to 74, and 60 (4.0%) 75 to 84 years. Among this sample, 166 (10.96%; 95% CI, 9.38%-12.52%) reported nonprescription opioid use within the past 12 months, including 114 (7.52%; 95% CI, 6.20%-8.85%) of the 1515 respondents reporting IMF use. Among those reporting nonprescription opioid use within the past 12 months, 65 (39.16%; 95% CI, 31.73%-46.58%) reported that their first opioid use involved opioids prescribed to them, whereas 60 (36.14%; 95% CI, 28.84%-43.45%) reported that their first use involved prescription opioids not prescribed to them. Only 41 (24.70%; 95% CI, 18.14%-31.26%) answered that their first exposure involved illicit opioids. Seventy-one (4.69%; 95% CI, 3.62%-5.75%) of all respondents reported that it was very likely they would have an overdose due to opioid use. This rate increased to 33.33% (95% CI, 24.68%-41.99%) among those who had used IMF within the past 12 months. Illicit opioid use was higher among men, Black respondents, and younger age groups. Conclusions and Relevance: The findings of this cross-sectional study indicate a higher prevalence of illicit opioid use than previously reported, highlighting the need for more timely and accurate data to inform policy and intervention strategies. Enhanced data collection efforts are essential for understanding and mitigating the opioid crisis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.